MARIUS, Trøseid, JR ARRIBAS, Assoumou LAMBERT, Holten ALEKSANDER, Poissy JULIEN, Terzić VIDA, Mazzaferri FULVIA, Jesús RODRÍGUEZ-BAÑO, Eustace JOE, Hites MAYA, Joannidis MICHAEL, Paiva JOSÉ, Reuter JEAN, Püntmann ISABEL, Thale Dawn PATRICK-BROWN, Elin WESTERHEIM, Katerina NEZVALOVA-HENRIKSEN, Beniguel LYDIE, Dahl TUVA and Costagliola DOMINIQUE. Efficacy and Safety of Baricitinib for the Treatment of Hospitalized Adults with Severe or Critical COVID-19 (Bari-SolidAct): A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Trial. Critical Care. LONDON: BMC, vol. 27, No 1, p. 1-15. ISSN 1364-8535. doi:10.1186/s13054-022-04205-8. 2023.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Efficacy and Safety of Baricitinib for the Treatment of Hospitalized Adults with Severe or Critical COVID-19 (Bari-SolidAct): A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Trial.
Authors MARIUS, Trøseid, JR ARRIBAS, Assoumou LAMBERT, Holten ALEKSANDER, Poissy JULIEN, Terzić VIDA, Mazzaferri FULVIA, Jesús RODRÍGUEZ-BAÑO, Eustace JOE, Hites MAYA, Joannidis MICHAEL, Paiva JOSÉ, Reuter JEAN, Püntmann ISABEL, Thale Dawn PATRICK-BROWN, Elin WESTERHEIM, Katerina NEZVALOVA-HENRIKSEN, Beniguel LYDIE, Dahl TUVA and Costagliola DOMINIQUE.
Edition Critical Care, LONDON, BMC, 2023, 1364-8535.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30230 Other clinical medicine subjects
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW SolidAct
Impact factor Impact factor: 15.100 in 2022
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1186/s13054-022-04205-8
UT WoS 000992268000002
Keywords (in Czech) COVID-19; immunomodulator; safety; baricitinib; JAK inhibitor
Keywords in English COVID-19; immunomodulator; safety; baricitinib; JAK inhibitor
Tags Excelence Science, MU, neMU, RIV, rivok, článek v časopise
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 17/1/2024 12:02.
Abstract
Background: The oral, selective Janus kinase 1/2 inhibitor baricitinib has shown efficacy in mixed populations of hospitalised participants with COVID-19. Bari-SolidAct is the first trial in the investigator-initiated, adaptive platform trial EU-SolidAct, and is a multinational, phase 3, randomised, double-blind, placebo-controlled trial of baricitinib in hospitalised patients with confirmed SARS-CoV-2 infection. We aimed to evaluate the efficacy and safety of baricitinib plus standard of care in hospitalised adults with severe or critical COVID-19.
Links
90249, large research infrastructuresName: CZECRIN IV
PrintDisplayed: 28/3/2024 18:02